Trump’s HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm
• When tiny Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it didn’t issue stock on the open market. Instead, it offered a sweetheart deal to “sophisticated U.S. investors,” company documents show.
Read More »
